CD274 and cancer: Although PD-L1 expression, mismatch-repair, and TMB are considered potential biomarkers to predict efficacy of various immune therapies, growing evidence suggests other factors like neutrophil to lymphocyte ratio (NLR), lactate dehydrogenase (LDH), and Ki-67 might be valuable markers for prognosis in cancer patients receiving immune therapy.